DU
SNDX icon

Delphia (USA)’s Syndax Pharmaceuticals SNDX Stock Holding History

Delphia (USA)’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,740
Closed -$204K – 486
2022
Q1 		$204K Buy
+11,740
New +$198K 0.15% 276

Other funds holding SNDX

APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Delphia (USA)'s SNDX Position: Q2 2022 in Review

Delphia (USA) sold out of Syndax Pharmaceuticals (SNDX) in Q2 2022, closing a stake of 11,740 shares — an estimated $204K sold.

Delphia (USA) first reported a position in SNDX in Q1 2022 and held it in 1 quarter. The position peaked at $204K in Q1 2022. 121 funds tracked by Wall St. Rank hold SNDX as of Q2 2022.

  • Delphia (USA) reported no remaining Syndax Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Delphia (USA) sold 11,740 Syndax Pharmaceuticals shares in Q2 2022, an estimated $204K.
  • Delphia (USA) first reported a position in Syndax Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Delphia (USA)'s Syndax Pharmaceuticals position peaked at $204K in Q1 2022.
  • 121 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2022.

Based on Delphia (USA)'s 13F filing for Q2 2022, filed 15 Aug 2022.